Objective:
To evaluate the efficacy and safety of EYP-1901 compared to aflibercept in patients with diabetic macular edema (DME).
Key Findings:
- 73% of high-dose EYP-1901 treated eyes were supplement-free at week 24 compared to 50% in the aflibercept arm.
- Significant improvement in best-corrected visual acuity (BCVA) observed as early as week 4.
- 40% to 50% of patients in EYP-1901 arms were free of DME at week 24, while 0% in the aflibercept arm.
- No serious adverse events related to EYP-1901 were reported.
Interpretation:
EYP-1901 demonstrated durable anti-VEGF activity and improved visual outcomes in DME patients compared to aflibercept, with a favorable safety profile.
Limitations:
- The study was limited to a 24-week duration.
- Long-term efficacy and safety data are still needed.
Conclusion:
VERONA phase 2 study indicates that EYP-1901 is a promising treatment for DME, showing superior efficacy and safety compared to aflibercept, warranting further investigation in phase 3 trials.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.